NCT06161519View on ClinicalTrials.gov

PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

November 14, 2028

Study Completion Date

November 14, 2033

Conditions
GliomaMedulloblastomaEpendymoma
Interventions
DRUG

PLX038

PLX038 is given intravenously (IV) at the assigned dose level over about 1 hour on day 1 of each 21-day cycle

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT06161519 - PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications | Biotech Hunter | Biotech Hunter